Psoriasis - Identifying and Commercializing First-in-Class I

1. Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation

2. Summary • GBI Research has released the pharma report: “Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation”, which identifies and assesses first-in-class innovation in the psoriasis development pipeline. • Over the last decade, a greater understanding of the underlying pathophysiology of psoriasis has increased emphasis on developing immuneomodulating therapies, as opposed to largely symptomatic treatments. This is currently reflected in a competitive market dominated by multiple disease-modifying biologic therapies (inhibitors of TNF-a and IL-12/IL-23) and generic small-molecule therapies. Despite this, there are significant unmet needs in the market, including safety concerns regarding immunomodulation. This is a particularly important issue for the long-term commercial and clinical success of psoriatic therapeutics, especially for emerging biologics. Another unmet need is ease of drug application, as biologic drug delivery is invasive and painful.

3. Summary This allows for pipeline programs that offer a more refined approach to immunomodulation and ease of drug application to gain market share upon entry. In a pipeline of over 200 programs, approximately one third exhibits a novel mechanism of action. Innovative programs target a wide range of molecules implicated in immune signaling, such as cytokines and B and T cell antigens. Several promising first-in-class therapies can selectively modulate specific subsets of immune cells without compromising the entire immune system. In particular, biologics that target a subset of T cells, which are strongly implicated in autoimmune pathophysiology, could allow for specificity of immune suppression and thereby reduce adverse side effects. Based on clinical trials, IL-17-targeted therapies have demonstrated superiority over currently established therapies in achieving advanced clinical endpoints. Get more about this report at: http://www.bigmarketresearch.com/frontier-pharma-psoriasis-identifying-and-commercializing-first-in-class-innovation-market

4. Scope • A brief introduction to psoriasis, including symptoms, pathophysiology, and overview of pharmacotherapy • The changing molecular target landscape between market and pipeline and particular focal points of innovation • Overview of how innovative products are contributing to the pipeline and market for psoriasis • Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of phase distribution, molecule type, molecular target, and administration route • Identification and assessment of first-in-class molecular targets with a particular focus on early-stage programs of which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets • Assessment of the licensing and co-development deals for psoriasis therapies • To Get More Details Enquire @ http://www.bigmarketresearch.com/report-enquiry/132449

5. Table Of Content 1 Table of Contents 2 The Case for Innovation 7 3 Clinical and Commercial Landscape 9 4 Assessment of Psoriasis Pipeline and Innovation 27 5 First-in-Class Target and Pipeline Program Evaluation 40 6 Deals and Strategic Consolidations 59 7 Appendix 66

6. FOR MORE DETAILS Visit us at : http://www.bigmarketresearch.com/frontier-pharma-psoriasis-identifying-and-commercializing-first-in-class-innovation-market Stay With Us: 5933 NE Win Sivers Drive,#205, Portland, OR 97220United States • TELEPHONE: +1 (855) 711-1555E-MAIL: sales@bigmarketresearch.com